Genor Biopharma Holdings Limited
HKSE: 6998.HK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Hong Kong Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Xin Ni
- Employees
- 24
- Headquarters
- Shanghai, China
- IPO year
- 2020
- Market cap
- HK$1.5B
- Website
- https://www.genorbio.com
Loading 6998…
Loading profile data…Frequently asked questions about 6998
What does Genor Biopharma Holdings Limited (6998.HK) do?
Genor Biopharma Holdings Limited, a biopharmaceutical company, focuses on developing and commercializing oncology and autoimmune drugs in China and internationally. The company's principal drug candidates include GB242, an infliximab (Remicade) biosimilar for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, adult ulcerat...
Where does 6998.HK trade?
Genor Biopharma Holdings Limited (6998.HK) trades on the Hong Kong Stock Exchange.
What sector is 6998.HK in?
Genor Biopharma Holdings Limited (6998.HK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Genor Biopharma Holdings Limited?
Xin Ni is the chief executive officer of Genor Biopharma Holdings Limited (6998.HK).
Where is Genor Biopharma Holdings Limited headquartered?
Genor Biopharma Holdings Limited is headquartered in China.
Does 6998.HK pay a dividend?
Genor Biopharma Holdings Limited (6998.HK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 6998.HK go public?
Genor Biopharma Holdings Limited (6998.HK) completed its initial public offering in 2020.